GLP-1/GIP Medication

Obesity or Overweight, adults 18 to 65

Locations: Manhattan (235 East 38th Street)

Cost to you: none for study visits, tests, or study medication

Questions: 516-574-9232 · Hablamos español

A Phase 2, randomized, placebo-controlled study of the safety, tolerability, and efficacy of an investigational GLP-1/GIP receptor agonist at different doses and titration schedules in adults living with overweight or obesity.
- Aged 18 to 65 years
- BMI of 30.0 or more and under 45.0 at screening, OR BMI of 27.0 or more with at least one weight-related condition: treated hypertension or blood pressure of 130/80 or higher; treated dyslipidemia or LDL-C of 160 mg/dL or more, triglycerides of 150 mg/dL or more, or HDL-C under 40 mg/dL (men) or under 50 mg/dL (women); prediabetes (treated, HbA1c 5.7% to under 6.5%, or two fasting glucose readings of 100 mg/dL or more); obstructive sleep apnea confirmed by a sleep study; established coronary artery disease; heart failure (NYHA Class II to III or a prior heart failure hospitalization); established peripheral artery disease; established cerebrovascular disease (stroke, TIA, or carotid or cerebral revascularization); or MASLD, including MASH
Gain access to cutting-edge medications and treatments before they are widely available.
Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.
We are highly focused on patient well-being and the highest ethical standards in clinical research.